Methylgene Inc.
Description MethylGene Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for cancer and infectious diseases. Its lead product candidates include MGCD265, an orally administered small molecule kinase inhibitor that is in Phase I/II clinical trials for the treatment of solid tumor indications, including liver, renal cell, gastric, prostate, colorectal, bladder, breast, ovarian, and non-small cell lung cancers; and MGCD290, an oral small molecule inhibitor of the fungal enzyme Hos2, which has completed Phase II trial for the treatment of vulvovaginal candidiasis. The company also develops mocetinostat (MGCD0103), an isoform selective histone deacetylase (HDAC) inhibitor that is in multiple Phase I and Phase II clinical trials for the treatment of hematological malignancies and solid tumors; and MG516, a kinase inhibitor that is in preclinical stage for the treatment of cancer. In addition, it develops MG96077, a beta-lactamase inhibitor to overcome antibiotic resistance; kinase inhibitors for ocular disease; and EVP-0334, a central nervous system penetrant HDAC inhibitor for neurodegenerative diseases. The company has license, and research and development collaboration agreement with Taiho Pharmaceutical Co. Ltd. for mocetinostat and small molecule HDAC inhibitor program for oncology; and research collaboration and license agreement with Otsuka Pharmaceutical Co. Ltd. for the development of novel, small molecule, kinase inhibitors for local delivery and treatment of ocular diseases. It also has a research, collaboration, and license agreement with EnVivo Pharmaceuticals, Inc. to exploit its HDAC inhibitors in diseases, such as Huntingtons, Parkinsons, and Alzheimers. The company was founded in 1995 and is headquartered in Montreal, Canada. To view the detailed information, you need to SUBSCRIBE with us. |
 |